EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high‐risk non‐muscle invasive bladder cancer in the UK (SPAN‐UK)

Jonathan Aning iD, James W F Catto, Rebecca Martin iD, Kathryn Chatterton, Paramananthan Mariappan, Edward Ottley iD, Joseph Hickey, Stephen McCormack, Simran Gill, Bernadett Szabados

BJUI Compass · 2026-07 · 7 (7)

DOI: 10.1002/bco2.70236 ↗

At a glance

Journal article in BJUI Compass, published online on 2026-06-28. Written by Jonathan Aning and 9 co-authors. Institution: Bristol Urological Institute North Bristol NHS Trust Bristol UK. 24 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Objectives

This study aimed to understand clinical pathways for patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) from diagnosis to follow‐up and to identify opportunities to improve care. Materials and Methods A cross‐sectional survey was conducted via structured online interviews with consented NHS healthcare professionals (HCPs) from the United Kingdom (UK) between June and September 2025. Topics surveyed included MDT structures/roles, diagnostic timelines, adjuvant treatment, radical cystectomy (RC) decision making, current bladder‐sparing treatment and clinical trial access. Quantitative data were analysed descriptively. Qualitative responses were analysed thematically.

Results

Seventy HCPs were included and reported that typically; 88.5% of patients achieve diagnosis within 6–8 weeks of referral, and 11.4% reported delays beyond 8 weeks. BCG maintenance duration and completion rates varied. Following BCG induction, a median (IQR) of 20.0% (5.0–32.5%) and 60.0% (40.0–70.0%) of patients completed ≥2 or ≤1 years of maintenance, respectively; 1.0% (1.0–2.0%) failed to complete induction. For BCG‐unresponsive HR‐NMIBC, HCPs reported that a mean ( SD ) proportion of 53.4 (18.1)% of patients tend to be eligible for and consent to RC, 22.0 (12.6)% tend to be eligible but decline RC and 24.6 (14.9)% tend to be ineligible. Bladder‐sparing options remain limited, with 60% of HCPs regarding further BCG as the most appropriate option. All respondents agreed that adherence to quality performance indicators (QPIs) and a national bladder cancer audit would be beneficial. Insufficient specialist nurse capacity to meet foreseeable demands of HR‐NMIBC patient care was reported by 70% ( n = 49) of HCPs.

Conclusion

Results reveal variability in real‐world HR‐NMIBC care within the NHS. Delays in diagnosis, inconsistent BCG maintenance duration, lack of evidence‐based alternatives to BCG and a lack of bladder‐sparing treatment and trial options in the BCG‐unresponsive setting were identified. Findings highlight unmet needs in relation to MDT resourcing, diagnostic efficiency, trial access, QPI adherence and a national bladder cancer audit.

Subjects

Author keywords

BCGHR‐NMIBCQPIbladder cancercross‐sectional surveynon‐muscle invasive bladder cancerradical cystectomyreal‐worldtreatment pathway

Authors and institutions

  • Bristol Urological Institute North Bristol NHS Trust Bristol UK.
  • Population Health Sciences, Bristol Medical School University of Bristol Bristol UK.
  • Division of Clinical Medicine, School of Medicine and Population Health University of Sheffield Sheffield UK.
  • The Royal Marsden NHS Foundation Trust London UK.
  • Guy's and St Thomas' NHS Foundation Trust London UK.
  • Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital University of Edinburgh Edinburgh UK.

ORCID profiles: Jonathan Aning, Rebecca Martin, Edward Ottley

Cite

APA

Aning, J., Catto, J. W. F., Martin, R., Chatterton, K., Mariappan, P., Ottley, E., Hickey, J., McCormack, S., Gill, S., & Szabados, B. (2026). State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high‐risk non‐muscle invasive bladder cancer in the UK (SPAN‐UK). BJUI Compass, 7(7). https://doi.org/10.1002/bco2.70236

Vancouver

Aning J, Catto JWF, Martin R, Chatterton K, Mariappan P, Ottley E, et al. State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high‐risk non‐muscle invasive bladder cancer in the UK (SPAN‐UK). BJUI Compass. 2026;7(7). doi:10.1002/bco2.70236

BibTeX
@article{Aning2026,
  author = {Aning, Jonathan and Catto, James W F and Martin, Rebecca and Chatterton, Kathryn and Mariappan, Paramananthan and Ottley, Edward and Hickey, Joseph and McCormack, Stephen and Gill, Simran and Szabados, Bernadett},
  title = {State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high‐risk non‐muscle invasive bladder cancer in the UK (SPAN‐UK)},
  journal = {BJUI Compass},
  year = {2026},
  volume = {7},
  number = {7},
  doi = {10.1002/bco2.70236}
}
Start for free →